A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia…

Service: Trial Number:
096-12
Principal Investigator: Conducted at:
Saddleback Memorial - Laguna Hills
Currently enrolling additional patients:
Yes

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy (Protocol EFC12492). The objective of the present study is to assess the efficacy and safety of SAR236553/REGN727 in patients with heterozygous familial hypercholesterolemia (heFH) and who require additional pharmacological management since their current lipid modifying therapy (LMT) failed to achieve the LDL-C treatment goal. This study is identical to 095-12 except the exclusion criteria is slightly different, excluding patients with LDL-C < 160 mg/dL instead of LDL-C <100 mg/dL.

MemorialCare Research Center Contact Form

For further information about this study or to express your interest in this study, please fill out and submit this form.
Address
,
 
The email to associate with this registration.